ArticleFrontiers in immunology2026
Establishment and phenotypic characterization of a rat model with a clinically relevant phenotype for chronic gouty arthritis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The study of chronic gouty arthritis (CGA) is limited by the absence of animal models that faithfully mimic its chronic progression. Existing models fail to capture the transition from acute flares to chronic joint damage, highlighting the need for a more representative model. Methods: A novel CGA model was established in SD rats using a combined strategy. Chronic hyperuricemia was induced via a diet containing 2% potassium oxonate and 12% yeast. This was supplemented with twice-weekly gavage of hypoxanthine to simulate acute uric acid fluctuations, followed by intra-articular injections of monosodium urate (MSU) crystals into the ankle and plantar region. This protocol lasted 10 weeks. Rats were divided into control, model, and allopurinol treatment groups. Evaluations included serum uric acid monitoring, joint swelling and inflammation scores, hindlimb hanging tests, histopathology, micro-CT, and inflammatory cytokine assays. Results: The model group exhibited sustained hyperuricemia with acute fluctuations, persistent joint swelling, significantly elevated inflammation scores (P<0.0001), and reduced hanging time (P<0.0001), indicating chronic pain and functional impairment. Histology revealed synovial hyperplasia, inflammatory cell infiltration, and cartilage damage. Micro-CT confirmed significant bone erosion, evidenced by an increased bone surface/bone volume ratio (P<0.001). Serum levels of IL-1β, TNF-α, and IL-6 were significantly elevated. Allopurinol treatment effectively lowered uric acid and alleviated joint swelling and bone erosion. Conclusion: This study successfully established and systematically characterized the phenotypic features of a CGA rat model that integrates chronic hyperuricemia, acute uric acid fluctuations, and local MSU crystal deposition. Phenotypically, this model recapitulates the core features of human CGA, including joint swelling, bone erosion, and functional impairment, thereby providing an experimental platform for investigating chronic joint damage induced by multiple interacting factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.